Biotech News

Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results

Arrowhead Pharmaceuticals (ARWR)Arrowhead PharmaceuticalsEarnings

- Conference Call and Webcast Today, November 12, 2026, at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Nov. 12, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2026 fiscal year ended September 30, 2026.

Related news

Arrowhead Pharmaceuticals

RNA Interference Platform Arrowhead Pharmaceuticals develops RNA interference medicines that silence disease-causing genes. Its delivery technologies support programs targeting the liver and other tissues. REDEMPLO REDEMPLO, or plozasiran, is an RNAi therapy targeting APOC3. It is approved in the United States to reduce triglycerides in...

Recent company news

Stock data

Close
43.65 USD
Market cap
9.98B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States